000129141 001__ 129141
000129141 005__ 20240228143411.0
000129141 0247_ $$2doi$$a10.18632/oncotarget.10295
000129141 0247_ $$2pmid$$apmid:27374106
000129141 0247_ $$2pmc$$apmc:PMC5216988
000129141 0247_ $$2altmetric$$aaltmetric:9270667
000129141 037__ $$aDKFZ-2017-05146
000129141 041__ $$aeng
000129141 082__ $$a610
000129141 1001_ $$aMascelli, Samantha$$b0
000129141 245__ $$aTP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma.
000129141 260__ $$a[S.l.]$$bImpact Journals LLC$$c2016
000129141 3367_ $$2DRIVER$$aarticle
000129141 3367_ $$2DataCite$$aOutput Types/Journal article
000129141 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521811303_19902
000129141 3367_ $$2BibTeX$$aARTICLE
000129141 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000129141 3367_ $$00$$2EndNote$$aJournal Article
000129141 520__ $$aPilocytic astrocytoma and ganglioglioma may occur in inaccessible or surgically difficult areas. In case of incomplete resection, the availability of biological predictors of tumour progression could be particularly important. To this end, an analysis of p53 codon 72 polymorphism and assessment of its role as prognostic marker were performed.The status of the p53 Arg72Pro polymorphism was evaluated by pyrosequencing method in a multicenter cohort of 170 paediatric patients. Genotype/phenotype associations were investigated either by means of bivariate or multivariate analyses.In the partially resected pilocytic astrocytomas, the Arg/Arg variant predicts early tumour progression (median survival time: 23.1 months) and is associated with poor event-free survival (p value = 0.0009). This finding remains true also in case of adjuvant therapies, with a 5-year event-free survival of 30.6% for cases with Arg/Arg variant vs. 78.7% for those with other genotypes. There is no association between ganglioglioma and the polymorphism.The assessment of Arg/Arg variant could improve the management of pilocytic astrocytoma. TP53 codon 72 analysis could distinguish low-risk cases, in which surgery could be conservative, from high-risk cases needing an aggressive surgery plan.
000129141 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000129141 588__ $$aDataset connected to CrossRef, PubMed,
000129141 7001_ $$aNozza, Paolo$$b1
000129141 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b2$$udkfz
000129141 7001_ $$aColin, Carole$$b3
000129141 7001_ $$aPistorio, Angela$$b4
000129141 7001_ $$aMilanaccio, Claudia$$b5
000129141 7001_ $$aRavegnani, Marcello$$b6
000129141 7001_ $$aConsales, Alessandro$$b7
000129141 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b8$$udkfz
000129141 7001_ $$aMorana, Giovanni$$b9
000129141 7001_ $$aCama, Armando$$b10
000129141 7001_ $$aCapra, Valeria$$b11
000129141 7001_ $$aBiassoni, Roberto$$b12
000129141 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b13$$udkfz
000129141 7001_ $$aFigarella-Branger, Dominique$$b14
000129141 7001_ $$aGarrè, Maria Luisa$$b15
000129141 7001_ $$aRaso, Alessandro$$b16
000129141 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.10295$$gVol. 7, no. 30, p. 47918 - 47926$$n30$$p47918 - 47926$$tOncoTarget$$v7$$x1949-2553$$y2016
000129141 909CO $$ooai:inrepo02.dkfz.de:129141$$pVDB
000129141 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000129141 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000129141 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000129141 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000129141 9141_ $$y2016
000129141 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000129141 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000129141 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000129141 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000129141 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000129141 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000129141 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000129141 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000129141 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000129141 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000129141 980__ $$ajournal
000129141 980__ $$aVDB
000129141 980__ $$aI:(DE-He78)B062-20160331
000129141 980__ $$aUNRESTRICTED